Pembrolizumab: a new standard of care in metastatic colorectal cancer

Immunotherapy. 2021 Oct;13(15):1245-1247. doi: 10.2217/imt-2021-0051. Epub 2021 Sep 20.

Authors

Khalil Saleh¹, Manal Kordahi², Tony Felefly³, Nadine Khalife⁴

Affiliations

¹ Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² National Institute of Pathology, Baabda, 1003, Lebanon.
³ Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon.
⁴ Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

PMID: 34542319
DOI: 10.2217/imt-2021-0051

No abstract available

Keywords: dMMR/MSI-H; immune checkpoint inhibitors; ipilimumab; metastatic colorectal cancer; nivolumab; pembrolizumab.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / immunology
Colorectal Neoplasms / pathology
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Standard of Care*

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
pembrolizumab